Anti-αIIbβ3 Immunization in Glanzmann Thrombasthenia: Prevalence and Associated Risk Factors: Thrombasthenia Anti-αIIbβ3 Antibodies Study (TAAS)

Clinical trial NCT04595617 · COMPLETED

Trial details

NCT number: NCT04595617
Sponsor: University Hospital, Bordeaux
Status: COMPLETED
Phase: Not Applicable
Study type: INTERVENTIONAL

Glanzmann Thrombasthenia

Start date: 2021-01-06
Primary completion: 2023-07-06
Enrollment: 28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.